Medical Research Council Technology: MRCT Dementia Consortium – New models to accelerate novel medicines to patients
Monday, November 17, 2014
2:55 PM - 3:20 PM
GH - Empire Ballroom I
The Dementia Consortium brings together research experts from charitable foundations, academia, and the private sector to accelerate discovery of new drugs for dementia by providing a pre-competitive environment for pharmaceutical partners to identify and advance early-stage fundamental research from academia. It provides funding, resources, and expertise to both increase and progress the number of new drug targets emerging from across the academic sector that hold promise of bringing patient benefit. Based on success to date, Medical Research Council Technology (MRCT) is now creating a further consortium for neurodegeneration that draws on funding from charitable foundations covering all areas of neurodegeneration research.
Dave Pardoe, Head of Growth Projects, Medical Research Council Technology
Mike Johnson, Director of Corporate Partnerships, Medical Research Council Technology
View the presentation slides as a PDF